Navigation Links
Oclaro Announces Second Quarter Fiscal Year 2013 Financial Results
Date:1/31/2013

ateNon-GAAP gross margin rate is calculated as gross margin rate as determined in accordance with GAAP (gross profit as a percentage of revenues) excluding non-cash compensation related to stock and options, purchase accounting adjustments related to the fair market value of acquired inventories and costs to outsource our back-end manufacturing activities. Oclaro evaluates its performance using non-GAAP gross margin rate to assess Oclaro's historical and prospective operating financial performance, as well as its operating performance relative to its competitors.

Non-GAAP Operating Income/LossNon-GAAP operating income/loss is calculated as operating income/loss as determined in accordance with GAAP excluding the impact of amortization of intangible assets, restructuring, acquisition and related costs, non-cash compensation related to stock and options granted to employees and directors, certain other one-time charges and credits and excluding any flood related advance payments received from insurers, impairment of fixed assets and inventory and related expenses specifically identified in the non-GAAP reconciliation schedules set forth below. Oclaro evaluates its performance using, among other things, non-GAAP operating income/loss in evaluating Oclaro's historical and prospective operating financial performance, as well as its operating performance relative to its competitors.

Non-GAAP Net Income/LossNon-GAAP net income/loss is calculated as net income/loss excluding the impact of restructuring, acquisition and related costs, gain on bargain purchase, Thailand flood-related income and expenses, non-cash compensation related to stock and options granted to employees and directors, net foreign currency translation gains/losses, the impact of amortization of intangible assets and certain other one-time charges and credits specifically identified in the non-GAAP reconciliation schedules set forth below. Oclaro uses non-GAAP net income/los
'/>"/>

SOURCE Oclaro, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Oclaro Announces Fourth Quarter and Fiscal Year 2012 Financial Results
2. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
3. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
4. Blue Belt Technologies Announces First U.S. Sale of NavioPFS Surgical System
5. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
6. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
7. Targovax AS Announces First Patient Included in Phase I/II Clinical Study With the Therapeutic Cancer Vaccine TG01 in Operable Pancreatic Cancer
8. Kemwell Announces Successful Pre-NDA US FDA Inspection
9. Cell Therapeutics Announces Data Safety and Monitoring Board Recommendation to Continue the GOG-0212 Phase 3 Clinical Trial of OPAXIOTM as Maintenance Therapy in Ovarian Cancer
10. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
11. Vanish Announces Tattoo Removal Giveaway for Valentines Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... SAN FRANCISCO , May 5, 2015 ... a Small Business Innovation Research (SBIR) grant from the ... Creek is a San Francisco ... therapeutics to selectively repair tissues damaged by disease. This ... therapeutics engineered to repair heart tissue following a heart ...
(Date:5/5/2015)... YORK , May 5, 2015  IBM Watson ... is collaborating with more than a dozen leading cancer ... and personalize treatment options for their patients. The institutes ... capabilities to reduce from weeks to minutes the ability ... and gather relevant information from medical literature to personalize ...
(Date:5/5/2015)... , May 5, 2015  The preclinical contract research ... pharmacokinetic testing of drugs and safety testing of medical ... Director of Preclinical Studies, presented at this week,s annual ... Ophthalmology (ARVO) in Denver, CO. ... Assessment of a Novel, Cross-Linked, Bio-Absorbable Carboxymethyl Hyaluronic Acid ...
Breaking Medicine Technology:Silver Creek Pharmaceuticals Awarded NIH SBIR Grant for Smart Growth Factor Technology 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... Yesterday, T he Lancet published online the ... Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®.  The 26-week ... plasma glucose (FPG), and body weight than Januvia®, with similar or ... , , ...
... April 23 Results of a ... g/d significantly improved lipid and glycemic measures in ... fasting glucose and/or impaired glucose tolerance).  The randomized, ... American Association of Clinical Endocrinologists (AACE) 19th Annual ...
Cached Medicine Technology:The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 2The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 3The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 4The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 5The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes 6New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 2New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 3New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 4New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 5New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 6New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 7New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 8New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 9New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes 10
(Date:5/5/2015)... 2015 ProTexting, LLC – a ... deploy Mobile Engagement Campaigns and other Mobile solutions, introduces ... can now leverage the power of Mobile Marketing to ... subscribers’ e-mail addresses into the Constant Contact Platform. , ... the growing trend of multi-channel marketing would become more ...
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Hope Initiative, a new study aimed at determining how ... patients. RG is an international non-profit providing rare disease ... sequencing technology, connections to scientists and researchers, and help ... crowdfunding. , “I am excited to see how crowdfunding ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 On April ... Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” ... LA’s leading producer of sustainable product placement in TV ... the world’s top providers of ecologically sound and socially ... premier red carpet event that makes appearances at various ...
(Date:5/5/2015)... Brookfield, Wis. (PRWEB) May 05, 2015 ... security solutions created the Sensatec® ST750 Fall Management Solution ... recording advising the monitored patient or resident to wait ... up. Caregivers also have the choice of 16 different ... into a nurse call system such as Code Alert®. ...
(Date:5/5/2015)... In the upbeat Moms Helping Moms video, real ... support each other. Parenting is a tough job, but ... so much easier. Mothers talk about how relating and ... and help them realize there’s no perfect parent; everyone is ... clearly dear friends share that it's just that, the friendship ...
Breaking Medicine News(10 mins):Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2
... ... within football’s international arena, it is with great pleasure that international direct selling identity, ... of Asian football. , ... (PRWEB) February 19, 2010 -- As the Official Direct Selling Supporter of the ...
... magnetic resonance imaging (MRI) may help physicians differentiate between ... wrist enabling more targeted therapies unique to each condition, ... the American Journal of Roentgenology . Contrast-enhanced MRI ... bodily structures. Rheumatoid arthritis ...
... ... ... ... ...
... ... , ... , , , , ... ...
... ... ... ... ...
... Francisco has signed a partnership agreement with Genentech, Inc., ... discover and develop drug candidates for neurodegenerative diseases. ... research acumen in neuroscience and will collaborate with UCSF ... work of several researchers at the UCSF Small Molecule ...
Cached Medicine News:Health News:QuestNet and AFC: Raising the Bar of Asian Football 2Health News:QuestNet and AFC: Raising the Bar of Asian Football 3Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 2Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 3Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 4Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 5Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 6Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 7Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 8Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 9Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 10Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 11Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 12Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 13Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 14Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 15Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 16Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 17Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 18Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 19Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 20Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 21Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 22Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 23Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 24Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 25Health News:Select Medical Holdings Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2009 26Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 2Health News:Biotel Announces Results for Second Quarter ended December 31, 2009 3Health News:Centene Corporation to Webcast Medical Management Systems Update 2Health News:Centene Corporation to Webcast Medical Management Systems Update 3Health News:Centene Corporation to Webcast Medical Management Systems Update 4Health News:UCSF enters drug discovery agreement with Genentech 2Health News:UCSF enters drug discovery agreement with Genentech 3
Eye Bank Specular Microscope. Specular microscope for easy examination of corneal slice extracted from a donor....
... system uses prolene as thread-guide reducing time and ... Probe is inserted into the nasolacrimal duct and ... The probe is then withdrawn leaving the polypropylene ... diam silicone tubing into place. Newly coated with ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... conforms to natural anatomy of the ... on disposable inserter/dilator instrument for ease ... The Micro-Large plugs feature the unique ... shape of the eyelid. The slightly ...
Medicine Products: